Sugi Predict

Sugi Predict / Compounds / SCHEMBL7204195

SCHEMBL7204195

SCHEMBL7204195

CC(=O)c1csc2c(Br)cccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.37
▸ KMT2A Q03164 5/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ HDAC3 O15379 1/20 0.37
▸ HDAC4 P56524 1/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ HDAC7 Q8WUI4 1/20 0.37
▸ HDAC2 Q92769 1/20 0.37
▸ HDAC10 Q969S8 1/20 0.37
▸ HDAC11 Q96DB2 1/20 0.37
▸ HDAC8 Q9BY41 1/20 0.37
▸ HDAC6 Q9UBN7 1/20 0.37
▸ HDAC9 Q9UKV0 1/20 0.37
▸ HDAC5 Q9UQL6 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ GAA P10253 2/20 0.36
▸ PRNP P04156 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ BRPF1 P55201 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6130740 0.84 PRNP (0.47) MEN1KMT2AKDM4EHDAC3HDAC4
SCHEMBL29244548 0.83 KMT2A (0.41) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL30935758 0.83 KMT2A (0.41) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL30935769 0.83 HDAC3 (0.37) MEN1KMT2AKDM4EHDAC3HDAC4
SCHEMBL29244563 0.83 HDAC3 (0.37) MEN1KMT2AKDM4EHDAC3HDAC4
SCHEMBL10689526 0.81 BRPF1 (0.47) MEN1KMT2AKDM4EHDAC3HDAC4
SCHEMBL29244550 0.80 MEN1 (0.38) MEN1KMT2AHDAC3HDAC4HDAC1
SCHEMBL30935765 0.80 MEN1 (0.38) MEN1KMT2AHDAC3HDAC4HDAC1
SCHEMBL15595505 0.79 KMT2A (0.40) MEN1KMT2AKDM4EHDAC3HDAC4
SCHEMBL7551013 0.77 GAA (0.48) KMT2AKDM4EALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117986235-A P53-Y220C selective small molecule reactivation agent compound, pharmaceutical composition and application thereof 长春金赛药业有限责任公司 2024-05-07 — — CN disclosed
EP-1274706-A1 PYRAZOLES FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2003-01-15 — — EP disclosed
US-6462069-B2 KINASE INHIBITORS; ANTICANCER AGENTS AGOURON PHARMACEUTICALS, INC. 2002-10-08 — — US disclosed
WO-2001079198-A9 PYRAZOLES FOR INHIBITING PROTEIN KINASE AGOURON PHARMA (US) 2002-05-16 — — WO disclosed
US-20020006952-A1 Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases LIGHPOINTE COMMUNICATION, INC. 2002-01-17 — — US disclosed
WO-2001079198-A1 PYRAZOLES FOR INHIBITING PROTEIN KINASE AGOURON PHARMACEUTICALS, INC. (US) 2001-10-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006952-A1 Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases CDK3, CCNK, CDK1 MEN1 4356/4885KMT2A 3744/4885KDM4E 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.